BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 30824700)

  • 1. Tyrosine phosphorylation activates 6-phosphogluconate dehydrogenase and promotes tumor growth and radiation resistance.
    Liu R; Li W; Tao B; Wang X; Yang Z; Zhang Y; Wang C; Liu R; Gao H; Liang J; Yang W
    Nat Commun; 2019 Mar; 10(1):991. PubMed ID: 30824700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical Role of 6-Phosphogluconate Dehydrogenase in TAp73-Mediated Cancer Cell Proliferation.
    Qiao R; Wei M; Chen H; Zhang X; Zhang J; Gao L; Ma H; Wang Y; Li L
    Mol Cancer Res; 2023 Aug; 21(8):825-835. PubMed ID: 37071129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 6-Phosphogluconate dehydrogenase fuels multiple aspects of cancer cells: From cancer initiation to metastasis and chemoresistance.
    Sarfraz I; Rasul A; Hussain G; Shah MA; Zahoor AF; Asrar M; Selamoglu Z; Ji XY; Adem Ş; Sarker SD
    Biofactors; 2020 Jul; 46(4):550-562. PubMed ID: 32039535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 6-Phosphogluconate dehydrogenase regulates tumor cell migration in vitro by regulating receptor tyrosine kinase c-Met.
    Chan B; VanderLaan PA; Sukhatme VP
    Biochem Biophys Res Commun; 2013 Sep; 439(2):247-51. PubMed ID: 23973484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lysine acetylation activates 6-phosphogluconate dehydrogenase to promote tumor growth.
    Shan C; Elf S; Ji Q; Kang HB; Zhou L; Hitosugi T; Jin L; Lin R; Zhang L; Seo JH; Xie J; Tucker M; Gu TL; Sudderth J; Jiang L; DeBerardinis RJ; Wu S; Li Y; Mao H; Chen PR; Wang D; Chen GZ; Lonial S; Arellano ML; Khoury HJ; Khuri FR; Lee BH; Brat DJ; Ye K; Boggon TJ; He C; Kang S; Fan J; Chen J
    Mol Cell; 2014 Aug; 55(4):552-65. PubMed ID: 25042803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycolytic cancer cells lacking 6-phosphogluconate dehydrogenase metabolize glucose to induce senescence.
    Sukhatme VP; Chan B
    FEBS Lett; 2012 Jul; 586(16):2389-95. PubMed ID: 22677172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
    Lin R; Elf S; Shan C; Kang HB; Ji Q; Zhou L; Hitosugi T; Zhang L; Zhang S; Seo JH; Xie J; Tucker M; Gu TL; Sudderth J; Jiang L; Mitsche M; DeBerardinis RJ; Wu S; Li Y; Mao H; Chen PR; Wang D; Chen GZ; Hurwitz SJ; Lonial S; Arellano ML; Khoury HJ; Khuri FR; Lee BH; Lei Q; Brat DJ; Ye K; Boggon TJ; He C; Kang S; Fan J; Chen J
    Nat Cell Biol; 2015 Nov; 17(11):1484-96. PubMed ID: 26479318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for a direct cross-talk between malic enzyme and the pentose phosphate pathway via structural interactions.
    Yao P; Sun H; Xu C; Chen T; Zou B; Jiang P; Du W
    J Biol Chem; 2017 Oct; 292(41):17113-17120. PubMed ID: 28848047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gambogic acid exhibits promising anticancer activity by inhibiting the pentose phosphate pathway in lung cancer mouse model.
    Zhang Q; Zhang Y; Wang C; Tang H; Ma A; Gao P; Shi Q; Wang G; Shen S; Zhang J; Xia F; Zhu Y; Wang J
    Phytomedicine; 2024 Jul; 129():155657. PubMed ID: 38692076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 6PGD inhibition sensitizes hepatocellular carcinoma to chemotherapy via AMPK activation and metabolic reprogramming.
    Chen H; Wu D; Bao L; Yin T; Lei D; Yu J; Tong X
    Biomed Pharmacother; 2019 Mar; 111():1353-1358. PubMed ID: 30841449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crystal Structures of 6-Phosphogluconate Dehydrogenase from
    Yu H; Hong J; Seok J; Seu YB; Kim IK; Kim KJ
    J Microbiol Biotechnol; 2023 Oct; 33(10):1361-1369. PubMed ID: 37417004
    [No Abstract]   [Full Text] [Related]  

  • 12. Inhibition of 6-Phosphogluconate Dehydrogenase Reverses Epirubicin Resistance Through Metabolic Reprograming in Triple-Negative Breast Cancer Cells.
    Xu J; Ren G; Cheng Q
    Technol Cancer Res Treat; 2023; 22():15330338231190737. PubMed ID: 37559469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibiting 6-phosphogluconate dehydrogenase enhances chemotherapy efficacy in cervical cancer via AMPK-independent inhibition of RhoA and Rac1.
    Guo H; Xiang Z; Zhang Y; Sun D
    Clin Transl Oncol; 2019 Apr; 21(4):404-411. PubMed ID: 30182212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blockade of 6-phosphogluconate dehydrogenase generates CD8
    Daneshmandi S; Cassel T; Lin P; Higashi RM; Wulf GM; Boussiotis VA; Fan TW; Seth P
    Cell Rep; 2021 Mar; 34(10):108831. PubMed ID: 33691103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. YTH domain family 2 promotes lung cancer cell growth by facilitating 6-phosphogluconate dehydrogenase mRNA translation.
    Sheng H; Li Z; Su S; Sun W; Zhang X; Li L; Li J; Liu S; Lu B; Zhang S; Shan C
    Carcinogenesis; 2020 Jul; 41(5):541-550. PubMed ID: 31504235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 6PGD Upregulation is Associated with Chemo- and Immuno-Resistance of Renal Cell Carcinoma via AMPK Signaling-Dependent NADPH-Mediated Metabolic Reprograming.
    Cao J; Sun X; Zhang X; Chen D
    Am J Med Sci; 2020 Sep; 360(3):279-286. PubMed ID: 32829780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PIKE-A promotes glioblastoma growth by driving PPP flux through increasing G6PD expression mediated by phosphorylation of STAT3.
    Sun M; Sheng H; Wu T; Song J; Sun H; Wang Y; Wang J; Li Z; Zhao H; Tan J; Li Y; Chen G; Huang Q; Zhang Y; Lan B; Liu S; Shan C; Zhang S
    Biochem Pharmacol; 2021 Oct; 192():114736. PubMed ID: 34411567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting 6-phosphogluconate dehydrogenase in the oxidative PPP sensitizes leukemia cells to antimalarial agent dihydroartemisinin.
    Elf S; Lin R; Xia S; Pan Y; Shan C; Wu S; Lonial S; Gaddh M; Arellano ML; Khoury HJ; Khuri FR; Lee BH; Boggon TJ; Fan J; Chen J
    Oncogene; 2017 Jan; 36(2):254-262. PubMed ID: 27270429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibiting 6-phosphogluconate dehydrogenase reverses doxorubicin resistance in anaplastic thyroid cancer via inhibiting NADPH-dependent metabolic reprogramming.
    Ma L; Cheng Q
    Biochem Biophys Res Commun; 2018 Apr; 498(4):912-917. PubMed ID: 29534964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 6-Phosphogluconate dehydrogenase (6PGD), a key checkpoint in reprogramming of regulatory T cells metabolism and function.
    Daneshmandi S; Cassel T; Higashi RM; Fan TW; Seth P
    Elife; 2021 Oct; 10():. PubMed ID: 34709178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.